3681 Stock Overview
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
SinoMab BioScience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.59 |
| 52 Week High | HK$1.95 |
| 52 Week Low | HK$1.03 |
| Beta | 0.72 |
| 11 Month Change | -3.05% |
| 3 Month Change | -12.64% |
| 1 Year Change | 0.63% |
| 33 Year Change | -54.05% |
| 5 Year Change | n/a |
| Change since IPO | -73.50% |
Recent News & Updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Shareholder Returns
| 3681 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.5% | 2.3% | -2.8% |
| 1Y | 0.6% | -28.3% | -6.7% |
Return vs Industry: 3681 exceeded the Hong Kong Biotechs industry which returned -28.3% over the past year.
Return vs Market: 3681 exceeded the Hong Kong Market which returned -6.7% over the past year.
Price Volatility
| 3681 volatility | |
|---|---|
| 3681 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 3681 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3681's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 215 | Shawn Leung | www.sinomab.com |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus.
SinoMab BioScience Limited Fundamentals Summary
| 3681 fundamental statistics | |
|---|---|
| Market cap | HK$1.74b |
| Earnings (TTM) | -HK$265.37m |
| Revenue (TTM) | HK$4.79m |
362.1x
P/S Ratio-6.5x
P/E RatioIs 3681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3681 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.39m |
| Cost of Revenue | CN¥943.00k |
| Gross Profit | CN¥3.45m |
| Other Expenses | CN¥246.56m |
| Earnings | -CN¥243.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 78.53% |
| Net Profit Margin | -5,535.31% |
| Debt/Equity Ratio | 132.4% |
How did 3681 perform over the long term?
See historical performance and comparison